An expanding role for interleukin-1 blockade from gout to cancer

Molecular Medicine

Volumn 20, Issue , 2014, Pages S43-S58

  Dinarello, Charles Anthony ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANAKINUMAB; GEVOKIZUMAB; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1ALPHA ANTIBODY; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACNE VULGARIS; ANKYLOSING SPONDYLITIS; ANTERIOR CRUCIATE LIGAMENT RUPTURE; ANTISYNTHETASE SYNDROME; ARTHRITIS; ARTHROFIBROSIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; BLAU SYNDROME; CACHEXIA; CALCIUM PYROPHOSPHATE ARTHRITIS; CHRONIC OSTEOMYELITIS; CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS; CINCA SYNDROME; CYTOKINE PRODUCTION; DEFICIENCY OF THE IL 1 RECEPTOR ANTAGONIST; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; GOUT; HAND OSTEOARTHRITIS; HEARING IMPAIRMENT; HEMOCHROMATOSIS; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KNEE INJURY; LEUKEMIA; MAJEED SYNDROME; MEVALONATE KINASE DEFICIENCY; MOLECULE; MONOTHERAPY; MUCKLE WELLS SYNDROME; MULTIPLE MYELOMA; MYOSITIS; NEOPLASM; NLRP12 AUTOINFLAMMATORY SYNDROME; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOARTHRITIS; PAPA SYNDROME; PATHOGENESIS; POLYCHONDRITIS; PROTEIN INDUCTION; PSEUDOANGIOMATOUS STROMAL HYPERPLASIA; PSEUDOGOUT; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; VASCULAR DISEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; FEVER; HEART DISEASE; METABOLISM;

ANIMALS; AUTOIMMUNE DISEASES; DIABETES MELLITUS, TYPE 2; FEVER; GOUT; HEARING LOSS; HEART DISEASES; HUMANS; INTERLEUKIN-1; NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922518882     PISSN: 10761551     EISSN: 15283658     Source Type: Journal    
DOI: 10.2119/molmed.2014.00232     Document Type: Article

References (308)

1. Dinarello CA, Renfer L, Wolff SM. (1977) Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc. Natl. Acad. Sci. U. S. A. 74:4624–7.
2. Murphy PA, Chesney PJ, Wood WB Jr. (1974) Further purification of rabbit leukocyte pyrogen. J. Lab. Clin. Med. 83:310–22.
3. Kawakami M, Pekala PH, Lane MD, Cerami A. (1982) Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells. Proc. Natl. Acad. Sci. U. S. A. 79:912–6.
4. Dinarello CA, et al. (1986) Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J. Exp. Med. 163:1433–50.
5. Dinarello CA. (1984) Interleukin-1 and the pathogenesis of the acute-phase response. N. Engl. J. Med. 311:1413–8.
6. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. (1989) Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 2:244–7.
7. Buchan G, et al. (1988) Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin. Exp. Immunol. 73:449–55.
8. Dayer JM, Beutler B, Cerami A. (1985) Cachectin/ tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J. Exp. Med. 162:2163–8.
9. Saklatvala J. (1986) Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 322:547–9.
10. Cerami A. (2011) The value of failure: the discovery of TNF and its natural inhibitor erythropoietin. J. Intern. Med. 269:8–15.
11. Alten R, et al. (2011) Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study. BMC Musculoskelet. Disord. 12:153.
12. Abbate A, Canada JM, Van Tassell BW, Wise CM, Dinarello CA. (2014) Interleukin-1 blockade in rheumatoid arthritis and heart failure: a missed opportunity? Int. J. Cardiol. 171:e125–6.
13. Van Tassell BW, et al. (2012) Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One. 7:e33438.
14. So A, et al. (2010) Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum. 62:3064–76.
15. So A, De Smedt T, Revaz S, Tschopp J. (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9:28.
16. Schlesinger N, et al. (2011) Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double- blind, randomised study. Ann. Rheum. Dis. 70:1264–71.
17. Terkeltaub R, et al. (2009) The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann. Rheum. Dis. 68:1613–7.
18. Hong DS, et al. (2014) MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: an open-label, phase 1 doseescalation and expansion study. Lancet Oncol. 15:656–66.
19. Netea MG, et al. (2009) Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages. Blood. 113:2324–35.
20. Okamoto M, et al. (2009) Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1beta. J. Biol. Chem. 285:6477–88.
21. Levandowski CB, et al. (2013) NLRP1 haplotypes associated with vitiligo and autoimmunity increase interleukin-1beta processing via the NLRP1 inflammasome. Proc. Natl. Acad. Sci. U. S. A. 110:2952–6.
22. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J. (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201:1479–86.
23. Goldbach-Mansky R, et al. (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N. Engl. J. Med. 355:581–92.
24. Lachmann HJ, et al. (2009) In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J. Exp. Med. 206:1029–36.
25. Livneh A, et al. (1999) MEFV mutation analysis in patients suffering from amyloidosis of familial Mediterranean fever. Amyloid. 6:1–6.
26. Chae JJ, et al. (2003) Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol. Cell. 11:591–604.
27. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. (2001) Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat. Genet. 29:301–5.
28. Aksentijevich I, et al. (2002) De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatalonset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 46:3340–8.
29. de Koning HD, et al. (2006) Beneficial response to anakinra and thalidomide in Schnitzler’s syndrome. Ann. Rheum. Dis. 65:542–4.
30. Gattorno M, et al. (2007) Pattern of interleukin- 1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum. 56:3138–48.
31. Solle M, et al. (2001) Altered cytokine production in mice lacking P2X(7) receptors. J. Biol. Chem. 276:125–32.
32. Andrei C, et al. (2004) Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: Implications for inflammatory processes. Proc. Natl. Acad. Sci. U. S. A. 101:9745–50.
33. Quartier P, et al. (2011) A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin- 1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann. Rheum. Dis. 70:747–54.
34. Ruperto N, et al. (2012) Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 367:2396–406.
35. Ruperto N, et al. (2012) A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 64:557–67.
36. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. (2005) Rapid responses to anakinra in patients with refractory adult-onset Still’s disease. Arthritis Rheum. 52:1794–803.
37. Kalliolias GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis SN. (2007) Anakinra treatment in patients with adult-onset Still’s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann. Rheum. Dis. 66:842–3.
38. Laskari K, Tzioufas AG, Moutsopoulos HM. (2011) Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still’s disease: a case-series study. Arthritis Res. Ther. 13:91.
39. Iliou C, Papagoras C, Tsifetaki N, Voulgari PV, Drosos AA. (2013) Adult-onset Still’s disease: clinical, serological and therapeutic considerations. Clin. Exp. Rheumatol. 31:47–52.
40. de Koning HD, Schalkwijk J, van der Meer JW, Simon A. (2011) Successful canakinumab treatment identifies IL-1beta as a pivotal mediator in Schnitzler syndrome. J. Allergy Clin. Immunol. 128:1352–4.
41. de Koning HD, et al. (2013) Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler’s syndrome. Ann. Rheum. Dis. 72:1634–8.
42. Pesek R, Fox R. (2014) Successful treatment of Schnitzler syndrome with canakinumab. Cutis. 94:E11–12.
43. Szturz P, et al. (2011) Schnitzler syndrome: diagnostics and treatment. Klin. Onkol. 24:271–7.
44. Vanderschueren S, Knockaert D. (2013) Canakinumab in Schnitzler syndrome. Semin. Arthritis Rheum. 42:413–6.
45. Lust JA, et al. (2009) Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1β-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin. Proc. 84:114–22.
46. Bruck N, et al. (2011) Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J. Clin. Rheumatol. 17:23–7.
47. Durand M, Troyanov Y, Laflamme P, Gregoire G. (2011) Macrophage activation syndrome treated with anakinra. J. Rheumatol. 37:879–80.
48. Kahn PJ, Cron RQ. (2013) Higher-dose Anakinra is effective in a case of medically refractory macrophage activation syndrome. J. Rheumatol. 40:743–4.
49. Kelly A, Ramanan AV. (2008) A case of macrophage activation syndrome successfully treated with anakinra. Nat. Clin. Pract. Rheumatol. 4:615–20.
50. Loh NK, Lucas M, Fernandez S, Prentice D. (2012) Successful treatment of macrophage activation syndrome complicating adult Still disease with anakinra. Intern. Med. J. 42:1358–62.
51. Simon DW, Aneja R, Carcillo JA, Halstead ES. (2014) Plasma exchange, methylprednisolone, IV immune globulin, and now anakinra support continued PICU equipoise in management of hyperferritinemia- associated sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome/ secondary hemophagocytic lymphohistiocytosis syndrome. Pediatr. Crit. Care Med. 15:486–8.
52. Schulert GS, Grom AA. (2014) Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies. Annu. Rev. Med. 2014, Nov 5 [Epub ahead of print].
53. Mohr V, et al. (2014) Urticaria, fever, and hypofibrinogenemia. Arthritis Rheumatol. 66:1377.
54. Tayer-Shifman OE, Ben-Chetrit E. (2013) Refractory macrophage activation syndrome in a patient with SLE and APLA syndrome – successful use of PETCT and Anakinra in its diagnosis and treatment. Mod. Rheumatol. 2013, Oct 21 [Epub ahead of print].
55. Ravelli A, Grom AA, Behrens EM, Cron RQ. (2012) Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment. Genes Immun. 13:289–98.
56. Opal SM, et al. (1997) Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial: the Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit. Care Med. 25:1115–24.
57. Singh D, Huston KK. (2009) IL-1 inhibition with anakinra in a patient with refractory gout. J. Clin. Rheumatol. 15:366.
58. Gratton SB, Scalapino KJ, Fye KH. (2009) Case of anakinra as a steroid-sparing agent for gout inflammation. Arthritis Rheum. 61:1268–70.
59. Ghosh P, Cho M, Rawat G, Simkin PA, Gardner GC. (2013) Treatment of acute gouty arthritis in complex hospitalized patients with anakinra. Arthritis Care Res. 65:1381–4.
60. Schumacher HR Jr, et al. (2012) Rilonacept (interleukin- 1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res. 64:1462–70.
61. Cronstein BN, Sunkureddi P. (2013) Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. J. Clin. Rheumatol. 19:19–29.
62. Giamarellos-Bourboulis EJ, et al. (2009) Crystals of monosodium urate monohydrate enhance lipopolysaccharide-induced release of interleukin 1 beta by mononuclear cells through a caspase 1- mediated process. Ann. Rheum. Dis. 68:273–8.
63. Joosten LA, et al. (2010) Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1beta production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum. 62:3237–48.
64. Duff GW, Atkins E, Malawista SE. (1983) The fever of gout: urate crystals activate endogenous pyrogen production from human and rabbit mononuclear phagocytes. Trans. Assoc. Am. Physicians. 96:234–45.
65. McGonagle D, et al. (2007) Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann. Rheum. Dis. 66:1683–4.
66. McGonagle D, Tan AL, Madden J, Emery P, McDermott MF. (2008) Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum. 58:631–3.
67. Terkeltaub R. (2010) Update on gout: new therapeutic strategies and options. Nat. Rev. Rheumatol. 6:30–8.
68. Announ N, Palmer G, Guerne PA, Gabay C. (2009) Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine. 76:424–6.
69. Schlesinger N, et al. (2012) Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann. Rheum. Dis. 71:1839–48.
70. Joosten LA, et al. (2009) Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum. 60:3651–62.
71. Bacconnier L, Jorgensen C, Fabre S. (2009) Erosive osteoarthritis of the hand: clinical experience with anakinra. Ann. Rheum. Dis. 68:1078–9.
72. Chevalier X, et al. (2005) Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J. Rheumatol. 32:1317–23.
73. Chevalier X, et al. (2009) Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebocontrolled study. Arthritis Rheum. 61:344–52.
74. Cohen SB, et al. (2011) A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL 1R1) in patients with osteoarthritis of the knee. Arthritis Res. Ther. 13:125.
75. Maedler K, et al. (2002) Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 110:851–60.
76. Donath MY, Shoelson SE. (2011) Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol. 11:98–107.
77. Masters SL, et al. (2010) Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat. Immunol. 11:897–904.
78. van Asseldonk EJ, et al. (2011) Treatment with anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab 96:2119–26.
79. Larsen CM, et al. (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356:1517–26.
80. Larsen CM, et al. (2009) Sustained effects of interleukin- 1 receptor antagonist treatment in type 2 diabetes. Diabetes Care. 32:1663–8.
81. Cavelti-Weder C, et al. (2012) Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care. 35:1654–62.
82. Rissanen A, Howard C, Botha J, Thuren T. (2011) IL-1beta antibody (canakinumab) improves insulin secretion rates in subjects with impaired glucose tolerance and type 2 diabetes. Diabetes. 60 Suppl 1.
83. Sloan-Lancaster J, et al. (2013) Double-blind, randomized study evaluating the glycemic and antiinflammatory effects of subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes Care. 36:2239–46.
84. Cavelti-Weder C, et al. (2011) Inhibition of IL- 1beta improves fatigue in type 2 diabetes. Diabetes Care. 34:e158s.
85. Norheim KB, Harboe E, Goransson LG, Omdal R. (2012) Interleukin-1 inhibition and fatigue in primary Sjogren’s syndrome: a double blind, randomised clinical trial. PLoS One. 7:e30123.
86. Stienstra R, et al. (2011) The inflammasomemediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell. Metab. 12:593–605.
87. Kamari Y, et al. (2007) Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism. Atherosclerosis. 195:31–8.
88. Duewell P, et al. (2010) NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 464:1357–61.
89. Libby P, Ridker PM, Hansson GK. (2009) Inflammation in atherosclerosis: from pathophysiology to practice. J. Am. Coll. Cardiol. 54:2129–38.
90. Ridker PM, Thuren T, Zalewski A, Libby P. (2011) Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti- inflammatory Thrombosis Outcomes Study (CANTOS). Am. Heart J. 162:597–605.
91. Ridker PM, et al. (2012) Effects of interleukin- 1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebocontrolled trial. Circulation. 126:2739–48.
92. Abbate A, et al. (2008) Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation. 117:2670–83.
93. Abbate A, et al. (2010) Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse. Eur. J. Heart Fail. 12:319–22.
94. Toldo S, et al. (2013) Interleukin-1beta blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse. Exp. Physiol. 98:734–45.
95. Abbate A, et al. (2010) Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am. J. Cardiol. 105:1371–77, e1371.
96. Abbate A, et al. (2013) Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCUART2) pilot study]. Am. J. Cardiol. 111:1394–400.
97. Van Tassell BW, et al. (2014) Effects of interleukin- 1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am. J. Cardiol. 113:321–7.
98. Pathak S, Goldofsky E, Vivas EX, Bonagura VR, Vambutas A. (2011) IL-1beta is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease. J. Immunol. 186:1870–9.
99. Vambutas A, et al. (2009) Alternate splicing of interleukin-1 receptor type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED. PLoS One. 4:e5293.
100. Vambutas A, et al. (2014) Early efficacy trial of anakinra in corticosteroid-resistant autoimmune inner ear disease. J. Clin. Invest. 124:4115–22.
101. Kitley JL, Lachmann HJ, Pinto A, Ginsberg L. (2010) Neurologic manifestations of the cryopyrin- associated periodic syndrome. Neurology. 74:1267–70.
102. Goldbach-Mansky R. (2011) Current status of understanding the pathogenesis and management of patients with NOMID/CINCA. Curr. Rheumatol. Rep. 13:123–31.
103. Kuemmerle-Deschner JB, et al. (2011) Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrinassociated periodic syndrome across different severity phenotypes. Ann. Rheum. Dis. 70:2095–102.
104. Klein AK, Horneff G. (2011) Improvement of sensoneurinal hearing loss in a patient with Muckle-Wells syndrome treated with anakinra. Klin. Padiatr. 222:266–8.
105. Lepore L, et al. (2011) Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J. Pediatr. 157:310–315, e311.
106. Miyamae T, et al. (2011) Effect of anakinra on arthropathy in CINCA/NOMID syndrome. Pediatr. Rheumatol. Online J. 8:9.
107. Neven B, et al. (2011) Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum. 62:258–67.
108. Mueller SM, Itin P, Haeusermann P. (2011) Muckle-Wells syndrome effectively treated with canakinumab: is the recommended dosing schedule mandatory? Dermatology. 223:113–8.
109. Kuemmerle-Deschner JB, et al. (2011) Canakinumab (ACZ885, a fully human IgG1 anti-IL-1beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Res. Ther. 13:34.
110. Kone-Paut I, et al. (2011) Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res. Ther. 13:202.
111. Lachmann HJ, et al. (2009) Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360:2416–25.
112. Furuta T, et al. (2011) Association of interleukin-1 gene polymorphisms with sudden sensorineural hearing loss and Meniere’s disease. Int. J. Immunogenet. 38:249–54.
113. Ogilvie AC, et al. (1996) IL-1 beta does not cause neutrophil degranulation but does lead to IL- 6, IL-8, and nitrite/nitrate release when used in patients with cancer. J. Immunol. 156:389–94.
114. Granowitz EV, et al. (1993) Hematological and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans. Blood. 82:2985–90.
115. Hoffman HM, et al. (2004) Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist prevents. Lancet. 364:1779–85.
116. Tewari A, Buhles WC Jr, Starnes HF Jr. (1990) Preliminary report: effects of interleukin-1 on platelet counts. Lancet. 336:712–4.
117. Janik JE, et al. (1996) Phase II trial of interleukin 1 alpha and indomethacin in treatment of metastatic melanoma. J. Natl. Cancer Inst. 88:44–9.
118. Lust JA, Donovan KA. (1999) The role of interleukin- 1 beta in the pathogenesis of multiple myeloma. Hematol. Oncol. Clin. North Am. 13:1117–25.
119. Berda-Haddad Y, et al. (2011) Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1alpha. Proc. Natl. Acad. Sci. U. S. A. 108:20684–9.
120. Kim B, et al. (2013) The interleukin-1alpha precursor is biologically active and is likely a key alarmin in the IL-1 family of cytokines. Front. Immunol. 4:391.
121. Kurt-Jones EA, Beller DI, Mizel SB, Unanue ER. (1985) Identification of a membrane-associated interleukin-1 in macrophages. Proc. Natl. Acad. Sci. U. S. A. 82:1204–8.
122. Kaplanski G, et al. (1994) Interleukin-1 induces interleukin-8 from endothelial cells by a juxacrine mechanism. Blood 84:4242–8.
123. Kaplanski G, et al. (1993) Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event. Blood. 81:2492–5.
124. Rider P, et al. (2011) IL-1α and IL-1β recruit different myeloid cells and promote different stages of sterile inflammation. J. Immunol. 187:4835–43.
125. Bersudsky M, et al. (2014) Non-redundant properties of IL-1alpha and IL-1beta during acute colon inflammation in mice. Gut. 63:598–609.
126. Bendtzen K, Svenson M, Jonsson V, Hippe E. (1990) Autoantibodies to cytokines: friends or foes? Immunol. Today. 11:167–9.
127. Svenson M, Poulsen LK, Fomsgaard A, Bendtzen K. (1989) IgG autoantibodies against interleukin 1 alpha in sera of normal individuals. Scand. J. Immunol. 29:489–92.
128. Chen CJ, et al. (2007) Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat. Med. 13:851–6.
129. Smith JW 2nd, et al. (1993) The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin. N. Engl. J. Med. 328:756–61.
130. Baracos V, Rodemann HP, Dinarello CA, Goldberg AL. (1983) Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1): a mechanism for the increased degradation of muscle proteins during fever. N. Engl. J. Med. 308:553–8.
131. Voronov E, et al. (2003) IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 100:2645–50.
132. Smith CJ, et al. (2012) Interleukin-1 receptor antagonist reverses stroke-associated peripheral immune suppression. Cytokine. 58:384–9.
133. Balkwill FR, Mantovani A. (2012) Cancer-related inflammation: common themes and therapeutic opportunities. Semin. Cancer Biol. 22:33–40.
134. Krelin Y, et al. (2007) Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. Cancer Res. 67:1062–71.
135. Dinarello CA. (2010) Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev. 29:317–29.
136. Dinarello CA. (2014) Interleukin-1alpha neutralisation in patients with cancer. Lancet Oncol. 15:552–3.
137. Dinarello CA, Simon A, van der Meer JW. (2012) Treating inflammation by blocking interleukin- 1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11:633–52.
138. Alenazi A, Al Sonbul A, Al Jumaah S, Al Mehaidib A, Al-Mayouf SM. (2012) A retrospective review of autoinflammatory diseases in Saudi children at a rheumatology clinic. Ann. Saudi Med. 32:43–8.
139. Calligaris L, Marchetti F, Tommasini A, Ventura A. (2008) The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. Eur. J. Pediatr. 167:695–6.
140. Chae JJ, et al. (2006) The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL- 1beta production. Proc. Natl. Acad. Sci. U. S. A. 103:9982–7.
141. Meinzer U, et al. (2011) Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin. Arthritis Rheum. 41:265–71.
142. Mitroulis I, Papadopoulos VP, Konstantinidis T, Ritis K. (2008) Anakinra suppresses familial Mediterranean fever crises in a colchicineresistant patient. Neth. J. Med. 66:489–91.
143. Moser C, et al. (2009) Successful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantation. Nephrol. Dial. Transplant. 24:676–8.
144. Ozen S, Bilginer Y, Aktay Ayaz N, Calguneri M. (2011) Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J. Rheumatol. 38:516–8.
145. Petropoulou AD, Robin M, Socie G, Galicier L. (2011) Transmission of familial Mediterranean fever mutation after bone marrow transplantation and successful treatment with anakinra. Transplantation. 90:102–3.
146. Stankovic Stojanovic K, et al. (2012) Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol. Dial. Transplant. 27:1898–901.
147. Bilginer Y, Ayaz NA, Ozen S. (2010) Anti-IL-1 treatment for secondary amyloidosis in an ado lescent with FMF and Behcet’s disease. Clin. Rheumatol. 29:209–10.
148. Soriano A, Verecchia E, Afeltra A, Landolfi R, Manna R. (2013) IL-1beta biological treatment of familial Mediterranean fever. Clin. Rev. Allergy Immunol. 45:117–30.
149. Akgul O, Kilic E, Kilic G, Ozgocmen S. (2013) Efficacy and safety of biologic treatments in Familial Mediterranean Fever. Am. J. Med. Sci. 346:137–41.
150. Estublier C, Stankovic Stojanovic K, Bergerot JF, Broussolle C, Seve P. (2013) Myositis in a patient with familial Mediterranean fever and spondyloarthritis successfully treated with anakinra. Joint Bone Spine. 80:645–9.
151. Ben-Zvi I, Livneh A. (2014) Colchicine failure in familial Mediterranean fever and potential alternatives: embarking on the anakinra trial. IMAJ. 16:271–3.
152. Hedrich CM, et al. (2012) “Mutation negative” familial cold autoinflammatory syndrome (FCAS) in an 8-year-old boy: clinical course and functional studies. Rheumatol. Int. 32:2629–36.
153. Metyas SK, Hoffman HM. (2006) Anakinra prevents symptoms of familial cold autoinflammatory syndrome and Raynaud’s disease. J. Rheumatol. 33:2085–7.
154. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. (2004) Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthr. Rheumat. 50:607–12.
155. Hawkins PN, Lachmann HJ, McDermott MF. (2003) Interleukin-1 receptor antagonist in the Muckle-Wells syndrome. N. Engl. J. Med. 348:2583–4.
156. Rynne M, Maclean C, Bybee A, McDermott MF, Emery P. (2006) Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism. Ann. Rheum. Dis. 65:533–4.
157. Kuemmerle-Deschner JB, et al. (2011) NLRP3 E311K mutation in a large family with Muckle- Wells syndrome: description of a heterogeneous phenotype and response to treatment. Arthritis Res. Ther. 13:196.
158. Kuemmerle-Deschner JB, et al. (2013) Treatment of Muckle-Wells syndrome: analysis of two IL- 1-blocking regimens. Arthritis Res. Ther. 15:64.
159. Stew BT, Fishpool SJ, Owens D, Quine S. (2013) Muckle-Wells syndrome: a treatable cause of congenital sensorineural hearing loss. B-ENT. 9:161–3.
160. Sabroe RA, et al. (2013) Muckle-Wells syndrome without mutation in exon 3 of the NLRP3 gene, identified by evidence of excessive monocyte production of functional interleukin 1beta and rapid response to anakinra. Clin. Exp. Dermatol.
161. Enriquez R, et al. (2013) Nephrotic syndrome and AA amyloidosis revealing adult-onset cryopyrin- associated periodic syndrome. Ren. Fail. 35:738–41.
162. Jeru I. (2011) Role of interleukin-1 in NLRP12- associated autoinflammatory disorders and resistance to anti–interleukin-1 therapy.
163. Lovell DJ, Bowyer SL, Solinger AM. (2005) Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatalonset multisystem inflammatory disease. Arthritis Rheum. 52:1283–6.
164. Sibley CH, et al. (2012) Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum. 64:2375–86.
165. Aubert P, et al. (2012) Homeostatic tissue responses in skin biopsies from NOMID patients with constitutive overproduction of IL-1beta. PLoS One. 7:e49408.
166. Balow JE Jr, et al. (2013) Microarray-based gene expression profiling in patients with cryopyrinassociated periodic syndromes defines a diseaserelated signature and IL-1-responsive transcripts. Ann. Rheum. Dis. 72:1064–70.
167. Sacre K, et al. (2008) Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy. J. Rheumatol. 35:357–8.
168. Simon A, et al. (2004) Beneficial response to interleukin-1 receptor antagonist in TRAPS. Am. J. Med. 117:208–10.
169. Gattorno M, et al. (2008) Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 58:1516–20.
170. Kimberley FC, Lobito AA, Siegel RM, Screaton GR. (2007) Falling into TRAPS: receptor misfolding in the TNF receptor 1-associated periodic fever syndrome. Arthritis Res. Ther. 9:217.
171. Cantarini L, Lucherini OM, Cimaz R, Galeazzi M. (2010) Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment. Clin. Exp. Rheumatol. 28:802.
172. Andres M, Pascual E. (2013) Anakinra for a refractory case of intermittent hydrarthrosis with a TRAPS-related gene mutation. Ann. Rheum. Dis. 72:155.
173. Lucherini OM, et al. (2013) First report of circulating microRNAs in tumour necrosis factor receptor- associated periodic syndrome (TRAPS). PLoS One. 8:e73443.
174. Bodar EJ, van der Hilst JC, Drenth JP, van der Meer JW, Simon A. (2005) Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth. J. Med. 63:260–4.
175. Cailliez M, et al. (2006) Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J. Inherit. Metab. Dis. 29:763.
176. Stoffels M, Simon A. (2011) Hyper-IgD syndrome or mevalonate kinase deficiency. Curr. Opin. Rheumatol. 23:419–23.
177. Simon A, van der Meer JW. (2007) Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292:86–98.
178. Bodar EJ, et al. (2011) On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann. Rheum. Dis. 70:2155–8.
179. Shendi HM, Walsh D, Edgar JD. (2012) Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome. Rheumatol. Int. 32:249–51.
180. Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. (2012) Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)--a new autoinflammatory syndrome distinct from PAPA syndrome. J. Am. Acad. Dermatol. 66:409–15.
181. Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. (2009) Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br. J. Dermatol. 161:1199–201.
182. Dierselhuis MP, Frenkel J, Wulffraat NM, Boelens JJ. (2005) Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology. 44:406–8.
183. Schellevis MA, et al. (2011) Variable expression and treatment of PAPA syndrome. Ann. Rheum. Dis. 70:1168–70.
184. Shoham NG, et al. (2003) Pyrin binds the PSTPIP1/ CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc. Natl. Acad. Sci. U. S. A. 100:13501–6.
185. Demidowich AP, et al. (2012) Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne). Arthritis Rheum. 64:2022–7.
186. Pazyar N, Feily A, Yaghoobi R. (2012) An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases. Curr. Clin. Pharmacol. 7:271–5.
187. Marzano AV, et al. (2013) Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet’s syndrome: a comprehensive review and disease classification criteria. Clin. Rev. Allergy Immunol. 45:202–10.
188. Reddy S, et al. (2009) An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N. Engl. J. Med. 360:2438–44.
189. Aksentijevich I, et al. (2009) An autoinflammatory disease with deficiency of the interleukin-1- receptor antagonist. N. Engl. J. Med. 360:2426–37.
190. Sakran W, et al. (2013) Chronic recurrent multifocal osteomyelitis and deficiency of interleukin- 1-receptor antagonist. Pediatr. Infect. Dis. J. 32:94.
191. Arostegui JI, et al. (2007) NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin- 1 blockade in a Spanish cohort. Arthritis Rheum. 56:3805–13.
192. Punzi L, Gava A, Galozzi P, Sfriso P. (2011) Miscellaneous non-inflammatory musculoskeletal conditions: Blau syndrome. Best Pract. Res. Clin. Rheumatol. 25:703–14.
193. Ruiz Gomez A, et al. (2012) Clinical, genetic, and therapeutic diversity in 2 patients with severe mevalonate kinase deficiency. Pediatrics. 129:e535–9.
194. Herlin T, et al. (2013) Efficacy of anti-IL-1 treatment in Majeed syndrome. Ann. Rheum. Dis. 72:410–3.
195. Adam Z, et al. (2008) Schnitzler syndrome: report on a fourteen-year course of the disease and an overview of information on the disease. Vnitr. Lek. 54:1140–53.
196. Cascavilla N, Bisceglia M, D’Arena G. (2010) Successful treatment of Schnitzler’s syndrome with anakinra after failure of rituximab trial. Int. J. Immunopathol. Pharmacol. 23:633–6.
197. De Koning HD, et al. (2006) Beneficial response to anakinra and thalidomide in Schnitzler’s syndrome. Ann Rheum Dis. 65:542–4.
198. Eiling E, Moller M, Kreiselmaier I, Brasch J, Schwarz T. (2007) Schnitzler syndrome: treatment failure to rituximab but response to anakinra. J. Am. Acad. Dermatol. 57:361–4.
199. Gran JT, Midtvedt O, Haug S, Aukrust P. (2011) Treatment of Schnitzler’s syndrome with anakinra: report of three cases and review of the literature. Scand. J. Rheumatol. 40:74–9.
200. Lipsker D. (2010) The Schnitzler syndrome. Orphanet J. Rare Dis. 5:38.
201. Martinez-Taboada VM, Fontalba A, Blanco R, Fernandez-Luna JL. (2005) Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al. Arthritis Rheum. 52:2226–7.
202. Schuster C, et al. (2009) Schnitzler syndrome: response to anakinra in two cases and a review of the literature. Int. J. Dermatol. 48:1190–4.
203. Larocca CA, et al. (2012) Schnitzler’s syndrome associated with pancreatitis: a disease of IL-1 dysregulation. Clin. Rheumatol. 31:169–74.
204. Benitez Gutierrez L, Mellor Pita S, Tutor de Ureta P, Yebra Bango M. (2013) [Schnitzler’s syndrome: a case report and literature review of the response to treatment with anakinra]. Med. Clin. (Barc.) 140:427–8.
205. Jain T, Offord CP, Kyle RA, Dingli D. (2013) Schnitzler syndrome: an under-diagnosed clinical entity. Haematologica. 98:1581–5.
206. Simon A, et al. (2013) Schnitzler’s syndrome: diagnosis, treatment, and follow-up. Allergy. 68:562–8.
207. Launay D, et al. (2013) Effect of in vitro and in vivo anakinra on cytokines production in Schnitzler syndrome. PLoS One. 8:e59327.
208. Volz T, et al. (2012) Dermal interleukin-1 expression and effective and long-lasting therapy with interleukin- 1 receptor antagonist anakinra in Schnitzler syndrome. Acta. Derm. Venereol. 92:393–4.
209. Furlan A, Botsios C, Ruffatti A, Todesco S, Punzi L. (2008) Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: a case report. Joint Bone Spine. 75:366–7.
210. Mesquida M, et al. (2014) Current and future treatments for Behcet’s uveitis: road to remission. Int. Ophthalmol. 34:365–81.
211. Kuemmerle-Deschner JB, et al. (2011) Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle- Wells syndrome. Arthritis Rheum. 63:840–9.
212. Leslie KS, et al. (2006) Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch. Dermatol. 142:1591–7.
213. Thornton BD, Hoffman HM, Bhat A, Don BR. (2007) Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin 1 receptor antagonist. Am. J. Kidney Dis. 49:477–81.
214. Ait-Abdesselam T, et al. (2011) Anakinra efficacy in a Caucasian patient with renal AA amyloidosis secondary to cryopyrin-associated periodic syndrome. Joint Bone Spine. 77:616–7.
215. Boyer EM, Turman M, O’Neil KM. (2011) Partial response to anakinra in life-threatening Henoch-Schonlein purpura: case report. Pediatr. Rheumatol. Online J. 9:21.
216. Picco P, et al. (2009) Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? Arthritis Rheum. 60:264–8.
217. Scott IC, Vijay Hajela V, Hawkins PN, Lachmann HJ. (2011) A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis. J. Cardiol. Cases. 4: e93–7.
218. Scardapane A, Brucato A, Chiarelli F, Breda L. (2013) Efficacy of an interleukin-1beta receptor antagonist (anakinra) in idiopathic recurrent pericarditis. Pediatr. Cardiol. 34:1989–91.
219. Seferovic PM, et al. (2013) Pericardial syndromes: an update after the ESC guidelines 2004. Heart Failure Rev. 18:255–66.
220. Camacho-Lovillo M, Mendez-Santos A. (2013) Successful treatment of idiopathic recurrent pericarditis with interleukin-1 receptor antagonist (Anakinra). Pediatr. Cardiol. 34:1293–94.
221. Paul SM, et al. (2005) Functional outcomes of treatment of neonatal onset multisystem inflammatory disease (NOMID) with anakina. Arthr. Rheumat. 52 Suppl:S536.
222. Gattorno M, et al. (2008) The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 58:1505–15.
223. Nigrovic PA, et al. (2011) Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 63:545–55.
224. DeWitt EM, et al. (2012) Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. Arthritis Care Res. (Hoboken). 64:1001–10.
225. Aelion JA, Odhav SK. (2004) Prompt response to treatment with anakinra in adult onset Still’s disease. Ann. Rheum. Dis. 63 Suppl 1:265.
226. Haraoui B, Bourrelle D, Kaminska E. (2004) Anakinra in the treatment of adult onset Still’s disease. Ann. Rheum. Dis. 63 Suppl 1:263.
227. Kotter I, et al. (2007) Anakinra in patients with treatment-resistant adult-onset Still’s disease: four case reports with serial cytokine measurements and a review of the literature. Semin. Arthritis Rheum. 37:189–97.
228. Lahiri M, Teng GG. (2010) A case of refractory adult-onset Still’s disease treated with anakinra. Int. J. Rheum. Dis. 13:e36–41.
229. Lequerre T, et al. (2008) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann. Rheum. Dis. 67:302–8.
230. Moulis G, Sailler L, Astudillo L, Pugnet G, Arlet P. (2010) May anakinra be used earlier in adult onset Still disease? Clin. Rheumatol. 29:1199–200.
231. Mylona E, et al. (2008) Acute hepatitis in adult Still’s disease during corticosteroid treatment successfully treated with anakinra. Clin. Rheumatol. 27:659–61.
232. Naumann L, et al. (2010) IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still’s disease. Ann. Rheum. Dis. 69:466–7.
233. Raffeiner B, et al. (2011) Adult-onset Still’s disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra. Joint Bone Spine. 78:100–1.
234. Rudinskaya A, Trock DH. (2003) Successful treatment of a patient with refractory adultonset Still’s disease with anakinra. J. Clin. Rheumatol. 9:330–2.
235. Tamaki H, et al. (2010) Marked effect and steroid-sparing ability of anakinra on a patient with refractory adult-onset Still’s disease. Mod. Rheumatol. 20:200–4.
236. Vasques Godinho FM, Parreira Santos MJ, Canas da Silva J. (2005) Refractory adult onset Still’s disease successfully treated with anakinra. Ann. Rheum. Dis. 64:647–8.
237. Vordenbaumen S, Ostendorf B, Sander O, Richter J, Schneider M. (2009) Continuation of anakinra despite the development of a pruritic rash in an otherwise refractory case of adultonset Still’s disease. Ann. Rheum. Dis. 68:450–1.
238. Youssef J, Lazaro E, Blanco P, Viallard JF. (2008) Blockade of interleukin 1 receptor in Still’s disease affects activation of peripheral T-lymphocytes. J. Rheumatol. 35:2453–6.
239. Woo P. (2008) Anakinra treatment for systemic juvenile idiopathic arthritis and adult onset Still disease. Ann. Rheum. Dis. 67:281–2.
240. Teran A, et al. (2009) Adult-onset Still’s disease with liver failure requiring liver transplantation. Gastroenterol. Hepatol. 32:681–6.
241. Rinkin C, Van Durme C, Fautrel B, Malaise M. (2013) A rare case of arthritis and fever. Revue medicale de Liege. 68:423–7.
242. Jaqua NT, Finger D, Hawley JS. (2012) Adultonset Still’s disease masquerading as sepsis in an asplenic active duty soldier. Case Rep. Med. 2012:349521.
243. Giampietro C, et al. (2013) Anakinra in adultonset Still’s disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res. 65:822–6.
244. Behrens EM, Kreiger PA, Cherian S, Cron RQ. (2006) Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. J. Rheumatol. 33:2081–4.
245. Aronson IK, Worobec SM. (2010) Cytophagic histiocytic panniculitis and hemophagocytic lymphohistiocytosis: an overview. Dermatol. Ther. 23:389–402.
246. Chou RC, Dinarello CA, Ferry JA, Dal Cin P. (2010) A 36-year-old woman with recurrent high-grade fevers, hypotension, and hypertriglyceridemia. Arthritis Care Res. 62:137–40.
247. Butin M, et al. (2013) Successful immunotherapy in life-threatening parvovirus B19 infection in a child. Pediatr. Infect. Dis. J. 32:789–92.
248. Delluc A, et al. (2008) Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome. Ann. Rheum. Dis. 67:278–9.
249. Kluger N, Gil-Bistes D, Guillot B, Bessis D. (2011) Efficacy of anti-interleukin-1 receptor antagonist anakinra (Kineret(R)) in a case of refractory Sweet’s syndrome. Dermatology. 222:123–7.
250. Belani H, et al. (2013) Neutrophilic urticaria with systemic inflammation: a case series. JAMA Dermatol. 149:453–8.
251. Lipsker D, Perrigouard C, Foubert A, Cribier B. (2010) Anakinra for difficult-to-treat neutrophilic panniculitis: IL-1 blockade as a promising treatment option for neutrophil-mediated inflammatory skin disease. Dermatology. 220:264–7.
252. Aouba A, et al. (2010) Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood. 116:4070–6.
253. Courcoul A, Vignot E, Chapurlat R. (2014) Successful treatment of Erdheim-Chester disease by interleukin-1 receptor antagonist protein. Joint Bone Spine. 81:175–7.
254. Aubert O, et al. (2013) Favorable radiological outcome of skeletal Erdheim-Chester disease involvement with anakinra. Joint Bone Spine. 80:206–7.
255. Colina M, et al. (2010) Dysregulation of P2X7 receptor- inflammasome axis in SAPHO syndrome: successful treatment with anakinra. Rheumatology (Oxford). 49:1416–8.
256. Eleftheriou D, et al. (2011) Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood. Rheumatology (Oxford). 49:1505–12.
257. Wendling D, Prati C, Aubin F. (2012) Anakinra treatment of SAPHO syndrome: short-term results of an open study. Ann. Rheum. Dis. 71:1098–1100.
258. Stojanov S, et al. (2011) Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade. Proc. Natl. Acad. Sci. U. S. A. 108:7148–53.
259. Cantarini L, et al. (2012) Typical and severe tumor necrosis factor receptor-associated periodic syndrome in the absence of mutations in the TNFRSF1A gene: a case series. Rheumatol. Int. 32:4015–8.
260. Galeotti C, et al. (2008) IL-1RA agonist (anakinra) in the treatment of multifocal Castleman disease. J. Pediatr. Hematol. Oncol. 30:920–4.
261. Sparsa L, et al. (2012) Jessner-Kanof disease induced by leflunomide: a dermal variant of cutaneous lupus? Rheumatol. Int. 31:255–8.
262. Cohen S, et al. (2012) A child with severe relapsing Kawasaki disease rescued by IL-1 receptor blockade and extracorporeal membrane oxygenation. Ann. Rheum. Dis. 71:2059–61.
263. van de Veerdonk FL, Netea MG, Dinarello CA, van der Meer JW. (2011) Anakinra for the inflammatory complications of chronic granulomatous disease. Neth. J. Med. 69:95.
264. de Luca A, et al. (2014) IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proc. Natl. Acad. Sci. U. S. A. 111:3526–31.
265. Leslie KS, Tripathi SV, Nguyen TV, Pauli M, Rosenblum MD. (2014) An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J. Am. Acad. Dermatol. 70:243–51.
266. Helmy A, et al. (2014) Recombinant human interleukin- 1 receptor antagonist in severe traumatic brain injury: a phase II randomized control trial. J. Cereb. Blood Flow Metab. 34:845–51.
267. Abramson SB, Amin A. (2002) Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford). 41:972–80.
268. Bresnihan B, Cobby M. (2003) Clinical and radiological effects of anakinra in patients with rheumatoid arthritis. Rheumatology (Oxford). 42 Suppl 2:ii22–86.
269. Bresnihan B, et al. (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41:2196–204.
270. Botsios C, et al. (2007) Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice: outcome in 60 patients with severe rheumatoid arthritis. Reumatismo. 59:32–7.
271. Singh JA, et al. (2010) Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Sao Paulo Med. J. 128:309–10.
272. Bao J, et al. (2011) Secondary failure to treatment with recombinant human IL-1 receptor antagonist in Chinese patients with rheumatoid arthritis. Clin. Rheumatol. 30:697–701.
273. Bresnihan B, Newmark RD, Robbins S, Mc- Cabe DP, Genant HK. (2000) Anakinra reduces the rate of joint destruction after 1 year of treatment in a randomized controlled cohort of patients with rheumatoid arthritis. Arthrit. Rheum. 43 Suppl S9-S289.
274. Bresnihan B, Newmark R, Robbins S, Genant HK. (2004) Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis: extension of a 24-week randomized, placebocontrolled trial. J. Rheumatol. 31:1103–11.
275. Jiang Y, et al. (2000) A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 43:1001–9.
276. Genant HK, et al. (2001) Treatment with anakinra reduces the rate of joint destruction and shows accelerated benefit in the second 6 months of treatment for patients with rheumatoid arthritis. Ann. Rheumat. Dis. 40 Suppl 1:169.
277. Cunnane G, Madigan A, Murphy E, FitzGerald O, Bresnihan B. (2001) The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology (Oxford). 40:62–9.
278. Devine EB, Alfonso-Cristancho R, Sullivan SD. (2011) Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. Pharmacotherapy. 31:39–51.
279. Wang SY, et al. (2011) Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis. J. Rheumatol. 38:821–7.
280. Turkstra E, Ng SK, Scuffham PA. (2011) A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. Curr. Med. Res. Opin. 27:1885–97.
281. Nixon R, Bansback N, Brennan A. (2007) The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons. Rheumatology (Oxford). 46:1140–7.
282. Cohen SB, Strand V, Aguilar D, Ofman JJ. (2004) Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy. Rheumatology (Oxford). 43:704–11.
283. Cohen SB. (2004) The use of anakinra, an interleukin- 1 receptor antagonist, in the treatment of rheumatoid arthritis. Rheum. Dis. Clin. North. Am. 30:365–80.
284. Kavanaugh A. (2006) Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis. Adv. Ther. 23:208–17.
285. Cohen SB, Woolley JM, Chan W. (2003) Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J. Rheumatol. 30:225–31.
286. Cohen SB, et al. (2004) A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann. Rheum. Dis. 63:1062–8.
287. Fleischmann RM, et al. (2003) Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo- controlled trial. Arthritis Rheum. 48:927–34.
288. Jansen JP, Buckley F, Dejonckheere F, Ogale S. (2014) Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs: a systematic review and network meta-analysis. Health Qual. Life Outcomes. 12:102.
289. Pontifex EK, et al. (2011) Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy: a single centre, open-label study. Arthritis Res. Ther. 13:R7.
290. Jung N, et al. (2011) An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). Clin. Rheumatol. 29:1169–73.
291. Brown C, Toth A, Magnussen R. (2011) Clinical benefits of intra-articular anakinra for persistent knee effusion. J. Knee Surg. 24:61–5.
292. Brown CA, Toth AP, Magnussen B. (2011) Clinical benefits of intra-articular anakinra for arthrofibrosis. Orthopedics. 33:877.
293. Kraus VB, et al. (2012) Effects of intraarticular IL1-Ra for acute anterior cruciate ligament knee injury: a randomized controlled pilot trial (NCT00332254). Osteoarthritis Cartilage. 20:271–8.
294. Chauffier K, London J, Beaudouin C, Fautrel B. (2009) Indications of anakinra. Presse Med. 38:799–807.
295. Buonuomo PS, et al. (2011) Relapsing polychondritis: new therapeutic strategies with biological agents. Rheumatol. Int. 30:691–3.
296. Vounotrypidis P, Sakellariou GT, Zisopoulos D, Berberidis C. (2006) Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra). Rheumatology (Oxford). 45:491–2.
297. Moore GH, Rootman DB, Roybal N, Goldberg RA. (2014) Orbital relapsing polychondritis: a unique presentation, complication, and treatment. Ophthal. Plast. Reconstr. Surg. 2014, Jul 28 [Epub ahead of print].
298. Rech J, et al. (2012) Adult-onset Still’s disease and chronic recurrent multifocal osteomyelitis: a hitherto undescribed manifestation of autoinflammation. Rheumatol. Int. 32:1827–9.
299. Haibel H, Rudwaleit M, Listing J, Sieper J. (2005) Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis.
300. Bennett AN, et al. (2008) Sustained response to anakinra in ankylosing spondylitis. Rheumatology (Oxford). 47:223–4.
301. Tan AL, et al. (2004) Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann. Rheum. Dis. 63:1041–5.
302. So A. (2010) Epidemiology: gout—bad for the heart as well as the joint. Nat. Rev. Rheumatol. 6:386–7.
303. Diamantopoulos AP, Brodin C, Hetland H, Haugeberg G. (2012) Interleukin 1beta blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment. J. Clin. Rheumatol. 18:310–11.
304. Molto A, Ea HK, Richette P, Bardin T, Liote F. (2012) Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis. Joint Bone Spine. 79:621–3.
305. Ottaviani S, et al. (2013) Efficacy of anakinra in calcium pyrophosphate crystal-induced arthritis: a report of 16 cases and review of the literature. Joint Bone Spine. 80:178–82.
306. Funck-Brentano T, et al. (2011) First observation of the efficacy of IL-1ra to treat tophaceous gout of the lumbar spine. Rheumatology (Oxford). 50:622–4.
307. Zong M, et al. (2014) Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann. Rheum. Dis. 73:913–20.
308. Latourte A, Frazier A, Briere C, Ea HK, Richette P. (2013) Interleukin-1 receptor antagonist in refractory haemochromatosis-related arthritis of the hands. Ann. Rheum. Dis. 72:783–4.